S&P Futures
4,580.00 +17.00 (+0.37%) Dow Futures
35,542.00 +97.00 (+0.27%) Nasdaq Futures
16,126.75 +78.75 (+0.49%) Russell 2000 Futures
1,810.50 +13.50 (+0.75%) Crude Oil
77.76 +1.35 (+1.77%) Gold
2,060.40 +0.20 (+0.01%)
Hoth Therapeutics, Inc. (HOTH)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 1.1000 |
| Open | 1.1186 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 1300 |
| Day's Range | 1.1100 - 1.1500 |
| 52 Week Range | 0.9900 - 12.5000 |
| Volume | |
| Avg. Volume | 219,952 |
| Market Cap | 4.955M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.7100 |
| Earnings Date | Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HOTH
Related Research
- Hoth Therapeutics, Inc.Daily – Vickers Top Insider Picks for 11/28/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic MoatyesterdayArgus Research
PR NewswireHoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.
- PR Newswire
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.
- PR Newswire
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.
